Gary Mason
Impact in
Papers in
-
- Prostate Cancer Treatment and Research 14
- Oncology 16
- PARP inhibition in cancer therapy 13
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- D. David Dershaw (1 shared paper)Laura Liberman (1 shared paper)Elizabeth A. Morris (1 shared paper)Ashok Panigrahy (4 shared papers)Ian F. Pollack (4 shared papers)Regina I. Jakacki (3 shared papers)Hideho Okada (3 shared papers)Matthew R. Smith (11 shared papers)
- Journals
- Journal of Clinical Oncology (9 papers)Annals of Oncology (3 papers)Neuro-Oncology (2 papers)Journal of Managed Care & Specialty Pharmacy (1 paper)Prostate Cancer and Prostatic Diseases (1 paper)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
Gary Mason
32 papers receiving 727 citations
Peers
Comparison fields: 5 of 58
- Genetics 132
- Oncology 250
- Pulmonary and Respiratory Medicine 263
- Radiology, Nuclear Medicine and Imaging 138
- Immunology 102
Countries citing papers authored by Gary Mason
This map shows the geographic impact of Gary Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Mason more than expected).
Fields of papers citing papers by Gary Mason
This network shows the impact of papers produced by Gary Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Mason. The network helps show where Gary Mason may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary Mason, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 144 | |
| 2 | 2022 | 82 | |
| 3 | 2019 | 73 | |
| 4 | 2016 | 70 | |
| 5 | 2013 | 58 | |
| 6 | 2016 | 53 | |
| 7 | 2016 | 40 | |
| 8 | 2015 | 40 | |
| 9 | 2021 | 29 | |
| 10 | 2020 | 24 | |
| 11 | 2015 | 21 | |
| 12 | 2020 | 17 | |
| 13 | 2023 | 12 | |
| 14 | 2023 | 10 | |
| 15 | 2016 | 7 | |
| 16 | 2023 | 6 | |
| 17 | 2024 | 6 | |
| 18 | 2017 | 6 | |
| 19 | 2016 | 6 | |
| 20 | 2019 | 5 |
About Gary Mason
Gary Mason is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Genetics, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 33 papers that have together received 737 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (14 papers), PARP inhibition in cancer therapy (13 papers), Glioma Diagnosis and Treatment (6 papers), Cancer Genomics and Diagnostics (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers), DNA Repair Mechanisms (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Genetics (132 citations), Oncology (250 citations), Pulmonary and Respiratory Medicine (263 citations), Radiology, Nuclear Medicine and Imaging (138 citations) and Immunology (102 citations). Gary Mason has collaborated with scholars based in United States, Australia and France. Frequent co-authors include D. David Dershaw, Laura Liberman, Elizabeth A. Morris, Ashok Panigrahy, Ian F. Pollack, Regina I. Jakacki, Hideho Okada, Matthew R. Smith, Lisa H. Butterfield and Shahneen Sandhu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Neuro-Oncology, Journal of Managed Care & Specialty Pharmacy and Prostate Cancer and Prostatic Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.